OnePin Peptide Library · Metabolic
AOD-9604
AOD9604 · AOD
AOD-9604 (Advanced Obesity Drug) is a synthetic 16-amino acid peptide corresponding to the C-terminal fragment (amino acids 176-191) of human growth hormone, with an additional tyrosine residue at the N-terminus. It was designed to isolate the fat-metabolizing activity of GH from its growth-promoting and diabetogenic effects. AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) through activation of the beta-3 adrenergic receptor pathway, without affecting IGF-1 levels, blood glucose, or insulin sensitivity. It underwent Phase 2 clinical trials for obesity but was not pursued to Phase 3 due to commercial rather than safety reasons. AOD-9604 is now also available as a chondroprotective agent under the brand name AOBG (Australia) for joint health.
Best administered in the morning on an empty stomach. Wait 30 minutes before eating. Some research protocols suggest injection into abdominal subcutaneous fat for localized effect. Fasted administration essential for fat metabolism effects.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
AOD-9604 activates beta-3 adrenergic receptors on adipocytes, stimulating hormone-sensitive lipase (HSL) and increasing lipolysis (triglyceride breakdown into free fatty acids and glycerol). Simultaneously, it inhibits lipogenesis by suppressing fatty acid synthase and acetyl-CoA carboxylase activity, reducing de novo fat formation. Unlike full-length GH, AOD-9604 does not activate the JAK2-STAT5 signaling pathway responsible for IGF-1 production, meaning it does not elevate IGF-1 levels or affect blood glucose homeostasis. The 4-minute plasma half-life means AOD-9604 acts primarily as a metabolic trigger rather than sustained signaling molecule. Its effects on fat metabolism are independent of growth hormone receptor activation. Additional chondroprotective effects have been documented, with AOD-9604 shown to stimulate proteoglycan synthesis in cartilage.
AOD-9604 activates beta-3 adrenergic receptors on adipocytes, stimulating hormone-sensitive lipase (HSL) and increasing lipolysis (triglyceride breakdown into free fatty acids and glycerol). Simultaneously, it inhibits lipogenesis by suppressing fatty acid synthase and acetyl-CoA carboxylase activity, reducing de novo fat formation. Unlike full-length GH, AOD-9604 does not activate the JAK2-STAT5 signaling pathway responsible for IGF-1 production, meaning it does not elevate IGF-1 levels or affect blood glucose homeostasis. The 4-minute plasma half-life means AOD-9604 acts primarily as a metabolic trigger rather than sustained signaling molecule. Its effects on fat metabolism are independent of growth hormone receptor activation. Additional chondroprotective effects have been documented, with AOD-9604 shown to stimulate proteoglycan synthesis in cartilage.
What to expect
Days 1-14: No significant visible changes. AOD works at the cellular level on lipid metabolism. No subjective effects expected (no hunger changes, no energy boost, no water retention).
Weeks 2-6: Body composition changes may begin to become apparent, particularly in combination with caloric deficit and exercise. DEXA or body composition measurements more reliable than scale weight.
Weeks 6-12: Cumulative fat loss effects. Phase 2 trials showed statistically significant weight loss vs placebo at 12 weeks. Most visible in stubborn fat areas when combined with proper nutrition. Lab work should confirm no changes in IGF-1, glucose, or insulin.
Evidence
The honest take
Fat loss without GH side effects
SupportedConfirmed by clinical trial data. AOD-9604 does not elevate IGF-1, does not affect glucose, and does not cause water retention or joint pain. This is its primary design advantage.
Injecting near target fat deposits is commonly discussed. There is no clinical data confirming localized fat reduction. The 4-minute half-life limits systemic distribution, which is the theoretical basis for this claim.
TGA (Australian Therapeutic Goods Administration) approved AOD-9604 as a food supplement for joint health. Proteoglycan synthesis stimulation demonstrated. Marketed as AOBG for osteoarthritis.
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Safe & synergistic
Keep separate
Side effects & safety
Commonly reported
- Very well tolerated in clinical trials
- Mild injection site reaction possible
- No significant side effects reported in Phase 2 data
Less common & notes
- Phase 2 trials showed a safety profile comparable to placebo.
- No effect on IGF-1, glucose homeostasis, or insulin sensitivity.
- No growth-promoting effects.
- The short 4-minute plasma half-life limits systemic exposure.
- Long-term data beyond 12 weeks is limited.
- AOD-9604 is one of the best-tolerated peptides available based on clinical trial safety data.
Pharmacokinetics
Storage. Store unreconstituted vials frozen (-20C) or refrigerated (2-8C). After reconstitution with BAC water, refrigerate at 2-8C. Stable for 28 days. Disulfide bridge adds structural stability. Protect from light. Inspect before use.
Regulatory status
WADA prohibits AOD-9604 under S0 Non-Approved Substances and S2 (peptide hormones category). FDA does not approve AOD-9604 for any human use. TGA (Australia) lists AOD-9604 as a scheduled substance for certain therapeutic uses. Available through research chemical and compounding channels.
Put it to work
Calculate, log & track
Open AOD-9604 straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open AOD-9604 in the app →Go deeper
The guide & community
The complete AOD-9604 walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗